Get the Stockscreener App
1.40
1.41%
-0.02
Medicinova Inc stock is traded at $1.40, with a volume of 2,203.
It is down -1.41% in the last 24 hours and down -7.89% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.42
Open:
$1.395
24h Volume:
2,203
Relative Volume:
0.17
Market Cap:
$69.16M
Revenue:
-
Net Income/Loss:
$-9.51M
P/E Ratio:
-7.3684
EPS:
-0.19
Net Cash Flow:
$-10.96M
1W Performance:
-0.71%
1M Performance:
-7.89%
6M Performance:
-32.37%
1Y Performance:
+5.26%
1-Day Range:
$1.395
$1.41
1-Week Range:
$1.37
$1.4537
52-Week Range:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.41 | 67.68M | 0 | -9.51M | -10.96M | -0.19 |
|
ONC
Beone Medicines Ltd Adr
|
246.33 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.61 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.23 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.26 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova: Q1 Earnings Snapshot - San Antonio Express-News
Barclays PLC Purchases 12,800 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Geode Capital Management LLC Raises Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - The Manila Times
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - GlobeNewswire
MediciNova Secures Spotlight at Exclusive Healthcare Conference: CEO to Reveal Latest Pipeline Progress - Stock Titan
Meta CEO Mark Zuckerberg takes the stand in historic antitrust trial - The Globe and Mail
MediciNova’s (MNOV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Texas Instruments (TXN) Stock Trades Down, Here Is Why - The Globe and Mail
First Patient Enrolled in NIH-Funded Expanded Access - GlobeNewswire
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - TradingView
This Stock Has More Than Doubled Already in 2025. Is It a Buy? - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
MEDICINOVA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Why AppLovin (APP) Shares Are Trading Lower Today - The Globe and Mail
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Carter's (CRI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid CSX and 1 Stock to Buy Instead - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Should You Forget Tesla and Buy 2 Artificial Intelligence (AI) Stocks Right Now? - The Globe and Mail
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MKS Instruments to Participate in Cantor Fitzgerald Global Technology Conference - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - The AM Reporter
MediciNova (NASDAQ:MNOV) Issues Earnings Results - MarketBeat
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs - The Globe and Mail
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):